# Proposal Status/Commentary

After a standard is proposed in *Pharmacopeial Forum* (*PF*) for public comment, the assigned Expert Committee reviews the comments and determines whether to approve the standard as a Revision, defer or cancel the standard. USP posts the lists of Revisions, Deferrals, Cancellations, and Commentary for each Issue of *USP–NF*.

- Revisions are items that have been proposed in PF, were approved by the assigned Expert Committee, and will appear in the noted
  publication. These items will have corresponding Commentary (see below).
- Deferrals are items that have been proposed in *PF* but are not yet approved by an Expert Committee. Items that have been deferred can be approved and published in a subsequent Issue of *USP–NF*. Some deferrals are later canceled.
- Cancellations are items that have been proposed in *PF* but will not move forward to ballot and subsequent publication. Canceled items may be re-proposed in a future *PF*.

Commentary is a summary of comments received and the assigned Expert Committee's responses. Commentary is published for Revisions only. In cases where proposals have been re-published in *PF*, only comments from the most recent *PF* publication are included in Commentary. Revisions, Deferrals, and Cancellations generally are posted prior to publication in *USP–NF Online*. Commentary is posted the same day the official text is published in *USP–NF Online*.

#### 2020-2024 Cumulative List of USP-NF Revisions (updated 29-Mar-2024)

The Cumulative List of *USP–NF* Revisions provides updated information on all items approved, deferred, or cancelled during the 2020-2025 Cycle. Cumulative List from 2015-2020 cycle can be found here.

## **USP-NF 2024, Issue 2**

• Deferrals (posted 27-Dec-2023)

- Cancellations (posted 27-Dec-2023)
- Revisions (posted 27-Dec-2023)
- Commentary (posted 01-Feb-2024)

# **USP-NF 2024, Issue 1**

- Deferrals (posted 29-Sep-2023)
- Cancellations (posted 29-Sep-2023)
- Revisions (posted 29-Sep-2023)
- Commentary (posted 01-Nov-2023; updated 26-Dec-2023)
- Monographs appearing in redesign format (posted 27-Dec-2023)

# **USP-NF 2023, Issue 3 (currently official)**

- Deferrals (posted 28-Apr-2023)
- Cancellations (posted 28-Apr-2023)
- Revisions (posted 28-Apr-2023)
- Commentary (posted 01-Jun-2023)

### **Previous USP-NF Issues**

Expand/collapse list

**USP-NF 2023** 

**USP-NF 2022** 

**USP-NF 2021** 

**USP 43-NF 38** 

**USP 42-NF 37** 

**USP 41-NF 36** 

**USP 40-NF 35** 

**USP 39-NF 34** 

**USP 38-NF 33** 

**USP 37-NF 32** 

**USP 36-NF 31** 

**USP 35-NF 30** 

**USP 34-NF 29** 

**USP 33-NF 28** 

**USP 32-NF 27** 

**USP 31-NF 26** 

**USP 30-NF 25** 

# **Interim Revision Announcements**

## IRAs published in 49(6)

- Norgestimate
- Zinc Acetate
- Zinc Chloride
- Zinc Sulfate

### IRAs published in 49(5)

- Commentary (posted 26-Jan-2024)
  - <64> Probiotic Tests

- · Lactobacillus acidophilus
- · Ligilactobacillus salivarius
- Commentary (posted 23-Feb-2024)
  - Sitigliptan Tablets

#### IRAs published in 49(4)

- Commentary (posted 26-Jan-2024)
  - Fosfomycin Tromethamine

#### IRAs published in 49(3)

No IRA proposals were published in PF 49(3)

- Commentary (posted 25-Aug-2023)
  - <660> Containers- Glass
  - <661.2> Plastic Packaging System for Pharmaceutical Use
- Commentary (posted 29-Sep-2023)
  - Phenoxybenzamine Hydrochloride

#### IRAs published in 49(2)

No comments were received when the following item was published:

• Bicalutamide Tablets

The following items were deferred:

- <660> Containers- Glass
- <661.2> Plastic Packaging Systems for Pharmaceutical Use
- Acyclovir
- Phenoxybenzamine Hydrochloride

### IRAs published in 49(1)

No IRA proposals were published in PF 49(1)

- Commentary (posted 26-May-2023)
  - Ziprasidone Hydrochloride

### **Previous PF Issues**

Expand/collapse list

Pharmacopeial Forum 48, Issues 1-6

Pharmacopeial Forum 47, Issues 1-6

Pharmacopeial Forum 46, Issues 1-6

Pharmacopeial Forum 45, Issues 1-6